UBS Group Portfolio holdings
UBS Group is the Swiss bank holding company behind UBS, which was created in 1998 when Union Bank of Switzerland merged with Swiss Bank Corporation; the holding company was listed in New York in 2014. Its business spans wealth management, investment banking, asset management and banking for individuals and companies. Its asset management arm offers stock, bond, currency, hedge fund, real estate, infrastructure and private equity strategies, which can also be combined in multi-asset portfolios. The group's roots go back to the Bank in Winterthur, founded in 1862, and to Swiss Bank Corporation, started by six private bankers in Basel by 1854. The wealth management arm serves high net worth individuals worldwide, and its US business grew out of Paine Webber, the American brokerage UBS merged with in 2000 and renamed UBS Wealth Management USA in 2003. In 2023 UBS took over Credit Suisse in a rescue deal arranged by the Swiss government and central bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.15B |
| 2 |
HONA
Honeywell Aerospace
HONA
|
+$611M |
| 3 |
SpaceX
SPCX
|
+$567M |
| 4 |
Apple
AAPL
|
+$511M |
| 5 |
Jabil
JBL
|
+$463M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.49B |
| 2 |
Western Digital
WDC
|
+$1.42B |
| 3 |
Lumentum
LITE
|
+$951M |
| 4 |
Intel
INTC
|
+$785M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$749M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 41.93% |
| 2 | Technology | 18.61% |
| 3 | Financials | 7.85% |
| 4 | Industrials | 6.96% |
| 5 | Healthcare | 5.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6376
Profound Medical
PROF
$263M
| $367K | ﹤0.01% |
55,224
-25,884
| -32% | -$174K |
2025 Q1
5 quarters
|
|
|
EMPG
6377
DELISTED
Empro Group
EMPG
| $367K | ﹤0.01% |
21,136
| – | – |
2025 Q3
3 quarters
|
|
6378
PUT
Harley-Davidson
HOG
$3.4B
| $367K | ﹤0.01% |
15,000
| – | – |
2024 Q3
7 quarters
|
|
6379
Putnam BDC Income ETF
PBDC
$278M
| $366K | ﹤0.01% |
13,454
+168
| +1% | +$4.6K |
2025 Q1
5 quarters
|
|
6380
Lyell Immunopharma
LYEL
$365M
| $365K | ﹤0.01% |
25,982
-5,832
| -18% | -$106K |
2021 Q3
19 quarters
|
|
6381
Knightscope
KSCP
$11.2M
| $362K | ﹤0.01% |
171,737
+60,059
| +54% | +$170K |
2024 Q4
6 quarters
|
|
6382
T. Rowe Price US High Yield ETF
THYF
$839M
| $362K | ﹤0.01% |
7,022
+6,865
| +4,373% | +$355K |
2026 Q1
1 quarter
|
|
6383
Radcom
RDCM
$172M
| $361K | ﹤0.01% |
25,603
+7,214
| +39% | +$101K |
2024 Q1
9 quarters
|
|
6384
Highland Global Allocation Fund
HGLB
$131M
| $361K | ﹤0.01% |
48,000
-25,732
| -35% | -$206K |
2023 Q1
13 quarters
|
|
6385
PUT
Banco Bradesco
BBD
$28.4B
| $361K | ﹤0.01% |
104,000
| – | – |
2026 Q1
1 quarter
|
|
6386
Immatics
IMTX
$968M
| $359K | ﹤0.01% |
35,433
-225,574
| -86% | -$2.38M |
2021 Q1
21 quarters
|
|
6387
Barings Participation Investors
MPV
$175M
| $359K | ﹤0.01% |
21,311
-331
| -2% | -$5.69K |
2014 Q4
46 quarters
|
|
6388
AN2 Therapeutics
ANTX
$151M
| $359K | ﹤0.01% |
74,086
+12,694
| +21% | +$54.6K |
2024 Q4
6 quarters
|
|
6389
CALL
NetApp
NTAP
$33.2B
| $356K | ﹤0.01% |
+2,300
| New | +$301K |
2026 Q2
0 quarters
|
|
6390
Defiance Daily Target 2x Short PLTR ETF
PLTZ
$43.6M
| $355K | ﹤0.01% |
+9,800
| New | +$298K |
2026 Q2
0 quarters
|
|
6391
Global X Hydrogen ETF
HYDR
$72.7M
| $354K | ﹤0.01% |
+6,675
| New | +$373K |
2026 Q2
0 quarters
|
|
6392
Torrid Holdings
CURV
$216M
| $352K | ﹤0.01% |
188,418
+183,481
| +3,716% | +$321K |
2022 Q3
15 quarters
|
|
6393
Diginex Ltd
DGNX
$34.4M
| $352K | ﹤0.01% |
237,718
+159,668
| +205% | +$330K |
2025 Q1
5 quarters
|
|
6394
Inflection Point Acquisition Corp VI
IPFX
$343M
| $351K | ﹤0.01% |
+33,962
| New | +$352K |
2026 Q2
0 quarters
|
|
6395
OneWater Marine
ONEW
$160M
| $351K | ﹤0.01% |
31,147
+2,389
| +8% | +$25.7K |
2024 Q1
9 quarters
|
|
6396
Standard BioTools
LAB
$251M
| $351K | ﹤0.01% |
425,977
+120,855
| +40% | +$114K |
2014 Q4
46 quarters
|
|
6397
Ponce Financial Group
PDLB
$525M
| $350K | ﹤0.01% |
17,551
-1,850
| -10% | -$33.8K |
2023 Q1
13 quarters
|
|
6398
MaxCyte
MXCT
$130M
| $350K | ﹤0.01% |
284,273
+13,219
| +5% | +$13.2K |
2021 Q3
19 quarters
|
|
6399
Invesco Bond Fund
VBF
$169M
| $349K | ﹤0.01% |
23,021
-2,479
| -10% | -$37.2K |
2014 Q4
46 quarters
|
|
6400
CS Disco
LAW
$372M
| $348K | ﹤0.01% |
92,124
-11,463
| -11% | -$44.4K |
2021 Q4
18 quarters
|
|
Similar funds
UBS Group's Q2 2026 Portfolio in Review
As of Q2 2026, UBS Group held 11,684 positions worth $786B, up 18% from $666B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
UBS Group's Q2 2026 filing shows 1,282 new, 4,216 increased, 4,362 reduced and 1,275 closed positions. Its largest new stake was Honeywell Aerospace: 2,768,136 shares worth $612M. The largest sale was ExxonMobil, an estimated $1.49B.
By sector, the portfolio is most concentrated in Miscellaneous at 42% of assets, up from 39% a quarter earlier, followed by Technology and Financials.
- UBS Group's largest Q2 2026 buy was Honeywell Aerospace: 2,768,136 shares worth $612M.
- UBS Group added most to Microsoft in Q2 2026, an estimated $1.15B increase.
- UBS Group's biggest Q2 2026 reduction was ExxonMobil, cutting an estimated $1.49B.
- UBS Group fully exited Hologic in Q2 2026, selling an estimated $385M.
- UBS Group's ten largest holdings make up 13% of its $786B portfolio in Q2 2026.
- UBS Group opened 1,282 new positions and closed 1,275 in Q2 2026.
- UBS Group's portfolio value rose 18% quarter-over-quarter to $786B.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.